Piramal Pharma Limited Financial Results Overview
Piramal Pharma Limited (NSE: PPLPHARMA) announced its financial results for the Second Quarter (Q2) and Half Year (H1) FY26, showcasing both challenges and opportunities in an evolving healthcare landscape. Despite facing inventory destocking issues impacting year-over-year (YoY) growth, the company remains committed to optimizing operations and enhancing its market position.
Consolidated Financial Highlights
For Q2 FY26, Piramal reported revenue from operations of ?2,044 crores, a decrease compared to the ?2,242 crores in Q2 FY25. This equates to a YoY drop of 9%. For H1 FY26, the revenue was ?3,977 crores, down by 5% from ?4,193 crores in H1 FY25.
The company's EBITDA margin for Q2 FY26 stood at 11%, while the half-year margin was at 10%. Although revenues were lower, this margin reflects the company’s effective cost management and operational improvements.
Key Performance Drivers and Future Outlook
Nandini Piramal, Chairperson of Piramal Pharma Limited, stated that the CDMO business faced hurdles due to soft demand from customers. However, recent trends indicate a rebound in biopharma funding, which is expected to stimulate order inflows and RFPs. The company is also focusing on enhancing its capabilities, particularly within its infrastructure for on-patent products.
Further, the company reported a significant reduction in net debt to ?3,971 crores, attributed to robust working capital management and strategic investment controls. As a result, its net debt to EBITDA ratio remains below 3x, showcasing financial health and sustainability.
Commitment to Sustainability
Piramal Pharma has published its Fourth Annual Sustainability Report, which highlights significant progress underlines its commitment to responsible innovation and sustainable growth. This report is validated by DNV Business Assurance India, ensuring accountability and transparency in its practices.
Business Highlights in the Market
The CDMO segment showcased mixed results among customer demands, particularly in inhalation products. Despite challenges, the company continues to reinforce its leadership position in certain markets. Key highlights include:
- Revenue growth challenges due to inventory adjustments by a major client.
- Increased funding activity in September and October 2025.
- Strategic advancements planned for product approvals in ex-US markets from their facilities in India.
Consumer Healthcare Growth Trajectory
Piramal Consumer Healthcare continues to display impressive growth, with power brands contributing notably to sales. The introduction of 26 new products in H1 FY26 reflects a robust pipeline and adaptability to market needs.
Upcoming Conference Call Details
Piramal Pharma will hold a conference call for investors on November 6, 2025, from 9:30 AM to 10:15 AM IST to discuss its financial results and strategic direction. This interactive session aims to provide insights into the company’s future growth strategies and operational updates.
Frequently Asked Questions
What were the key financial results for Q2 FY26?
The revenue was ?2,044 crores, representing a decline of 9% compared to the previous year.
What is the outlook for Piramal Pharma's CDMO business?
Despite current challenges, there is a positive trend with renewed funding in early FY26, which is expected to boost demand and order flow.
How is Piramal addressing its sustainability goals?
The company has released its sustainability report detailing efforts in responsible innovation and environmental commitments.
When will the next earnings call for investors be held?
The earnings call is scheduled for November 6, 2025, at 9:30 AM IST.
How is Piramal managing its financial health?
Piramal has reduced its net debt and maintained a favorable debt to EBITDA ratio, reflecting its financial discipline.
